Understanding of the genetic basis of autoimmune diseases is currently incomplete. Cytokine gene polymorphisms warrant consideration as factors explaining variation in the human immune and inflammatory responses and as candidate susceptibility genes for related pathological states. Interleukin 12 (IL-12) is a key regulator of the polarisation of immune responses to T helper 1 or 2 categories and plays a role in autoimmune and infectious diseases. Using a bioinformatic strategy, we aligned cDNA and expressed sequence tag sequences to identify putative polymorphic regions of the IL-12 p40 gene. Position 1188 in the 3Ј untranslated region (UTR) was polymorphic with the frequency of the common allele around 80% in healthy UK Caucasoids. PCR genotyping of multiple Caucasoid groups and an African group showed significant population variation. In a case-control design, the polymorphism was not associated with rheumatoid arthritis, Felty's syndrome or large granular lymphocyte syndrome with arthritis or multiple sclerosis. A nonsignificant increase in the B allele frequency was observed in the rare large granular lymphocyte syndrome without arthritis (odds ratio 2.02 95% CI 0.95-4.3). This new genetic marker could be useful in anthropological studies and should be investigated in other autoimmune, allergic, inflammatory and infectious diseases. Genes and Immunity (2000) 1, 219-224.
Introduction
Most immune-mediated diseases have a complex aetiology with an important role for genetic variation suggested by twin and other family studies. 1 The ultimate goal of genetic investigation is to demonstrate association of specific polymorphisms with disease phenotype leading to confirmation of functional effect. Favoured current approaches for the description of relevant genetic variation are genome scanning using the non-parametric affected sibling pair method and the candidate gene approach, either applied to a case control design or using a family-based linkage or association model. 2, 3 The identification of genetic polymorphisms which are associated with disease has, at best, been sporadic with the human leucocyte antigen (HLA) class I and class II genes the exception. Genes encoding cytokines, their receptors and their antagonist proteins are attractive candidates and have been intensively investigated. Polymorphisms of IL1beta, IL-1RA, IL-4R, IL-6 and IL-10 have been associated with a variety of autoimmune, inflammatory and infectious diseases. [4] [5] [6] [7] [8] [9] [10] [11] Genes encoding cytokines which determine the course of T cell mediated immune response are prime candidates as autoimmune disease susceptibility or severity genes. A key event in the course of an immune response is the differentiation of CD4 T lymphocytes. Under appropriate circumstances CD4 T cells differentiate into either T helper 1 (TH1) cells which produce IL-2, interferon gamma (IFN-␥) and tumour necrosis factor beta (TNF-␤), activate macrophages and cause delayed type hypersensitivity reactions; or into TH2 cells which produce IL4, IL-5 and IL-10, cause eosinophilia and are more specialised at providing B cell help. [12] [13] [14] The differentiation of T cells into either TH1 or TH2 cells is controlled by many different factors which include the nature and concentration of the antigen, its route of entry, the type of antigen presenting cell (APC) and the soluble factors secreted by the APC. Interleukin 12 (IL-12) is a proinflammatory cytokine which is produced by phagocytic cells, B cells and other APC's that modulate the adaptive immune response by favouring the generation of TH1 cells. 15, 16 IL-12 acts as a potent inducer of IFN-␥ production by T cells and natural killer cells. IFN-␥ stimulates phagocytic cells to produce IL-12 and other proinflammatory cytokines, therefore acts in a positive feedback loop to enhance the inflammatory response to infections.
Studies of differential production of IL-12 in BALB/c and DBA/2 mice suggest that strain specific variation which is not major histocompatibility complex (MHC) encoded affects IL-12 production with skewing of an antigen-specific recall response to either a TH1 or a TH2 direction. 17 In humans, deletions of IL-12 p40 and IL-12 12 receptors lead to serious impairment of immunity to intracellular bacteria. [18] [19] [20] IL-12 is therefore an important candidate in diseases which are the result of imbalances in immune regulation. Polymorphism of the IL-12 p40 gene has not been previously described or studied in immune-mediated diseases. A bioinformatic route to polymorphism discovery was taken for the IL-12 p40 gene. A common single nucleotide polymorphism (SNP) is described in the 3Ј untranslated region (UTR) of the IL-12 p40 gene and we describe significant normal population variation and examine the utility of this SNP in a number of autoimmune diseases.
Results

Population variation at the IL-12 p40 locus
The position 1188 polymorphism was detected by a comparison of multiple independent entries in the GenBank database. This approach is rapid, cost-effective and increasing in use as a means of mapping SNPs. 21 To confirm that the variation detected was due to a genetic polymorphism and not a PCR, cloning or sequencing artifact, a somatic mutation acquired during in vitro culture, or a rare mutation, we established a simple PCR genotyping assay and screened healthy donors from a number of European subpopulations and an ethnically distinct African group. The genotype and allele frequencies for the studied populations are given in Table 1 . All populations with the exception of the Northern Irish were in Hardy-Weinberg equilibrium. There is minor variation in allele frequency across the UK with B allele frequencies ranging from 13% in Manchester controls to 21% in London UK Controls-2. Allele frequencies also vary between the southern UK and Greek populations with the most extreme variation between the southern UK and Cameroon groups ( Table 2 , P Ͻ 0.0003). The highest frequency of the B allele found so far was in the Cameroon group (0.375) with the lowest in the UK control 2 group (0.129). Since variation amongst the three UK control groups was not significant, they were pooled for disease association comparisons. Variation between the Ioannina and Athens Greek controls was notable although not statistically significant. A common approach to establishing the evolutionary age of a polymorphism is to establish its presence in mans nearest relative, the chimpanzee. No variation was seen at the equivalent 1188 site in DNA from a chimpanzee population, although power calculations suggest a 95% confidence interval for the true B allele frequency of (0, 4.4)%.
Il-12 p40 1188 does not play a major role in RA susceptibility in UK whites and Greeks
To assess whether the IL-12 p40 1188 polymorphism is relevant to the development of rheumatoid arthritis (RA), genotypes were established in two population cohorts: 258 white UK RA patients compared with 255 local controls and 179 Greek RA patients with 159 Greek controls. There were no statistically significant distortions in the allele distributions between matched patient and control groups (see Tables 1 and 2 ).
IL-12 polymorphism in multiple sclerosis
Multiple sclerosis (MS) is an inflammatory autoimmune disease in which Th1 cells have been implicated and in which raised IL-12 levels correlate with disease activity. 22, 23 We investigated whether the IL-12 p40 polymorphism was relevant to multiple sclerosis susceptibility by genotyping a group of 77 MS patients and 86 local healthy controls from Northern Ireland. As the local Northern Ireland controls were not in Hardy-Weinberg equilibrium, the patient group was also compared to the combined UK control population. No significant genotype or allele distribution differences were observed suggesting that this marker alone is not a useful indicator of MS susceptibility in this population (see Tables 1 and 2 ).
IL-12 p40 B allele is non-significantly associated with large granular lymphocyte (LGL) syndrome in the absence of arthritis
Since IL-12 has been shown to be a growth/survival factor for large granular lymphocytes in vitro 24 and IL-12 therapy in vivo leads to the expansion of this cell population, 25 we tested whether IL-12 polymorphism was associated with several conditions in which LGL expansions are prominent. Genotyping was carried out in a group of LGL patients with arthritis, LGL patients without arthritis, Felty's syndrome patients without LGL expansions and local healthy controls. While the LGL with arthritis and the related Felty's syndrome groups showed similar genotype distributions to controls, there was an increase in B allele frequency in LGL patients without arthritis compared to the combined UK controls which just failed to reach significance ( Table 2 , P = 0.06). A total of 46.7% of LGL patients without arthritis were positive for the B allele compared to 30.2% controls with the increase accounted for by AB heterozygotes.
Discussion
We describe here the first polymorphism in the human IL-12 p40 gene, an SNP at position 1188 in the 3Ј untranslated region of the IL-12 p40 gene mapping to chromosome 5q31-33. Although the SNP is located in the 3Ј UTR and does not alter the coding sequence, it has utility as a genetic marker for this functionally important gene whose product is a major regulator of the direction of the immune response in both mice and humans. 14, 15 Since it has been postulated that inflammatory T helper 1 type cells play a major role in the pathogenesis of immunemediated diseases such as rheumatoid arthritis and multiple sclerosis, we examined the candidacy of this locus in two large groups of Northern and Southern European RA patients. No association was apparent suggesting that this polymorphism is uninformative with regard to RA susceptibility per se. We also examined the SNP in Felty's Genes and Immunity syndrome which is clinically more homogeneous than RA and which we have shown has stronger associations with the known RA genetic risk factor HLA-DRB1*04. [26] [27] [28] Again, there was no association, with allele frequencies almost indistinguishable between the groups. Since cancer patients receiving IL-12 therapy frequently develop physical expansions of large granular lymphocytes 25 and IL-12 has been shown along with IL-2 to stimulate growth of CD8 LGL in vitro, 24 we tested whether the IL-12 p40 SNP was associated with the development of large granular lymphocyte leukaemia.
LGL leukaemia is found with and without associated inflammatory arthritis. 27, 29 While LGL syndrome with arthritis was not associated with p40 variation, the B allele frequency was non-significantly raised in the group without arthritis (odds ratio 2.02, P = 0.06) with the effect due to increased frequency of heterozygotes. Our interpretation of this finding is limited by two factors. Firstly, LGL syndrome is very rare necessitating the establishment of an international collaboration to collect an adequate sample size. Here we studied 22 LGL syndrome patients with arthritis and 30 without. The statistical power of this comparison is therefore limited as is the practical capacity for replication of a positive or negative result. Secondly, although the LGL syndrome patients were all of white Northern European background, population variation in IL-12 p40 allele frequencies and population substructure might contribute to false positive results in an internationally mixed cohort. Balanced against this are our observations that for IL-10 and Fas polymorphisms, no population substructure effects were apparent in studies on similar patient and control groups with allele and genotype frequencies well matched. 30, 31 The mean age of LGL patients at diagnosis precludes a family association approach requiring parents, though studies using the sibling transmission disequilibrium test (TDT) approach may be possible in the future.
The significant variation in the allele and genotype distributions between African and Caucasoid population groups suggests that the IL-12 p40 polymorphism described here will be a useful addition to the range of genetic markers for future anthropological studies. Although the IL-12 p40 SNP was not significantly associated with any of the Th1 type immune-mediated diseases studied, it maps to a genomic region (5q31-33) which has been demonstrated to be linked to intensity of schistosomiasis infection, 32 circulating eosinophil levels,
33
CD4 T helper 2 differentiation 34 and quantitative phenotypes associated with asthma and atopy. 35, 36 There may be benefit in testing for association between this genetic marker and a range of allergic and infectious diseases in which activity or failure of T helper 2 type cells may play a prominent role.
Subjects and methods
UK rheumatoid arthritis
Two hundred and fifty-eight Caucasoid RA patients from England were investigated, all fulfilling the 1987 revised ACR criteria. 37 One hundred and twenty-four of these were derived from clinics at Guy's Hospital while 134 patient probands were derived from the ARC National Repository RA families. 38 A total of 90.1% of the patients were rheumatoid factor positive, 87% had definite erosions, and 83% were positive for HLA DR4.
Greek rheumatoid arthritis
Two RA groups from Greece were studied. Seventy-three RA patients from the University Hospital of Ioannina and 106 patients from University hospitals in the Athens Metropolitan area were studied. All patients fulfilled the 1987 revised ACR criteria 37 and details of the first group have been previously published. 39, 40 Ninety percent of the second RA group were rheumatoid factor positive by nephelometry, 25% were HLA-DR4 positive and 100% had definite erosions. Local controls were recruited and are described below.
Large granular lymphocyte and Felty's syndromes (FS)
Thirty-seven patients with FS which have been described previously were studied. 41 All fulfilled the ACR criteria for RA, 37 and in addition had a history of unexplained neutropenia (Ͻ2 × 10 9 L) for at least 6 months. Splenomegaly was not an essential criterion. The LGL syndrome was defined as the presence of Ͼ1 × 10 9 L LGL in the peripheral blood, persistent for at least 6 months. 29 LGLs were defined either by morphology or by immunophenotyping using fluorescent antibodies to CD3 and CD57. Since lymphopenia can be present in the LGL syndrome, an alternative criterion was the presence of LGLs comprising Ͼ25% of lymphocytes. Twenty-two patients with LGL and arthritis were recruited. Twelve of these have been described previously. 27 Two additional patients were recruited in the South East of England, and two from Sweden. Six patients from the USA were studied, and these have been described previously. 42 All fulfilled the ACR criteria for RA. Thirty patients with LGL but no arthritis were studied. Twelve of these have been previously described, 27 and a further three patients were recruited in the UK. Fifteen USA patients were also studied, and these have been described. 42 All patients, whether from the UK, Sweden or the USA, were of North European Caucasoid origin. 
Multiple sclerosis
PCR amplification and sequencing
The IL-12 p40 subunit is located on chromosome 5q31.1-33.1. PCR primers 1188 5Ј-TTCTATCTGATTTGCTTTA and 1188 3Ј-TGAAACATTCCATACATCC were used to amplify a 233-bp fragment from the IL-12 p40 subunit from genomic DNA. Twenty ng genomic DNA was amplified for 30 cycles of 95°C for 30 s, 43°C for 30 s and 72°C for 1 min with a final extension for 7 min at 72°C. Standard Promega Taq polymerase was used for the amplification with a final concentration of 2.5 mm MgCl and 200 m dNTP's. The amplified fragment covers position 1188 of the p40 gene which encodes either the nucleotide A (allele A), or C (allele B) which results in the creation of a Taq1 restriction enzyme site. All PCR products were digested with the restriction enzyme TaqI, which generated two products if allele B (1188-C) was present of size 68 and 165 base pairs, and remains uncut (233 bp) if allele A is present 1188-A). The restriction digested products were run out on a 2% agarose gel containing ethidium bromide and an appropriate size ladder. The frequency of this polymorphism was studied in control populations from the UK (England and Northern Ireland), Greece and the Cameroons, as well as in individuals with rheumatoid arthritis (UK and Greek populations), Felty's and LGL syndromes. Patients with multiple sclerosis patients included as a non-rheumatoid inflammatory disease control group. The IL-12 p40 PCR fragment was amplified and sequenced using DNA from 33 chimpanzees using conditions described above. Genotyping was carried out as above with sequencing using an Applied Biosystems ABI 377 automated DNA sequencer with the dRhodamine dye terminator kit (Perkin-Elmer-Applied Biosystems, Foster City, CA, USA) to confirm integrity of the area surrounding the restriction site.
Statistical methods
Genotype frequency comparisons were carried out using Fisher's exact test. Based on the given sample sizes, the power to detect the observed difference in allele B frequency between two populations was evaluated.
